GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » EBIT

Harmony Biosciences Holdings (Harmony Biosciences Holdings) EBIT : $213.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings EBIT?

Harmony Biosciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $56.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $213.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Harmony Biosciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was 37.50%. Harmony Biosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 77,150.68%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Harmony Biosciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 13.75%.


Harmony Biosciences Holdings EBIT Historical Data

The historical data trend for Harmony Biosciences Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings EBIT Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -145.90 -8.72 61.62 123.48 197.15

Harmony Biosciences Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.51 46.87 54.74 55.12 56.32

Competitive Comparison of Harmony Biosciences Holdings's EBIT

For the Biotechnology subindustry, Harmony Biosciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harmony Biosciences Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's EV-to-EBIT falls into.



Harmony Biosciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $213.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harmony Biosciences Holdings  (NAS:HRMY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Harmony Biosciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=208.132 * ( 1 - 25.97% )/( (406.935 + 414.892)/ 2 )
=154.0801196/410.9135
=37.50 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=811.448 - 117.224 - ( 353.46 - max(0, 163.781 - 451.07+353.46))
=406.935

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=846.985 - 106.843 - ( 372.35 - max(0, 154.253 - 479.503+372.35))
=414.892

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Harmony Biosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=225.28/( ( (0.371 + max(-51.171, 0)) + (0.213 + max(-32.1, 0)) )/ 2 )
=225.28/( ( 0.371 + 0.213 )/ 2 )
=225.28/0.292
=77,150.68 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(74.14 + 5.363 + 18.107) - (117.224 + 0 + 31.557)
=-51.171

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(79.719 + 5.857 + 21.577) - (106.843 + 0 + 32.41)
=-32.1

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Harmony Biosciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=213.048/1549.798
=13.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harmony Biosciences Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Executives
Peter Anastasiou director C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki director C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin officer: Chief Business Officer 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno officer: Chief Medical Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks officer: Chief Commercial Officer 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs director, officer: President, CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia officer: Chief Financial Officer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf director C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley director 1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii 10 percent owner 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611